Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Methotrexate nanotherapeutic - Cardiol Therapeutics

Next Previous
Drug Profile

Methotrexate nanotherapeutic - Cardiol Therapeutics

Alternative Names: CTX02

Latest Information Update: 28 Jun 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cardiol Therapeutics
  • Class Abortifacients; Anti-inflammatories; Antiasthmatics; Antifibrotics; Antineoplastics; Antipsoriatics; Antirheumatics; Benzamides; Cardiovascular therapies; Disease-modifying antirheumatics; Eye disorder therapies; Glutamates; Heart failure therapies; Pterins; Small molecules
  • Mechanism of Action Antimetabolites; Immunosuppressants; Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Heart failure

Most Recent Events

  • 28 Jun 2022 No recent reports of development identified for research development in Heart-failure in Canada
  • 13 Jun 2018 Chemical structure information added
  • 05 Jun 2018 Cardiol Therapeutics plans a phase I trials for Heart failure in the first half of 2019 (Cardiol Therapeutics pipeline, June 2018)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top